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Aim: Mycophenolic acid (MPA), is the active form of the ester prodrug mycophenolate mofetil 
(MMF). MMF is an FDA approved immunosuppressive drug that has been successfully 
used in systemic therapy in combination with other agents for the prevention of acute 
rejection (AR) following solid organ transplantation (SOT) as well as in vascularized composite 
allotransplantation (VCA). Systemic use of MMF is associated with gastrointestinal adverse 
effects. Topical delivery of the prodrug could thus provide graft-targeted immunosuppression 
while minimizing systemic drug exposure. Our goal was to develop a topical formulation of 
MPA with optimal in vitro/in vivo characteristics such as release, permeation, and tissue 
bioavailability to enable safety and efficacy evaluation in clinical VCA.
Materials and Methods: Permeation studies were performed with a solution of MPA 
(10 mg/ml). In vitro release and permeation studies were performed for different semisolid 
formulations (Aladerm, Lipoderm, emollient, and VersaBase) of MPA (1% w/w) using a Franz 
Diffusion Cell System (FDCS). In vivo pharmacokinetic characterization of MPA release from 
Lipoderm was performed in rats.
Results: MPA in solution exhibited a steady state flux (3.8 ± 0.1 µg/cm2/h) and permeability 
(1.1 × 10−7 ± 3.2 × 10−9 cm/s). MPA in Lipoderm exhibited a steady state flux of 1.12 ± 
0.24 µg/cm2/h, and permeability of 6.2 × 10−09 ± 1.3 × 10−9 cm/s across the biomimetic 
membrane. The cumulative release of MPA from Lipoderm, showed a linear single-phase 
profile with a R2 of 0.969. In vivo studies with MPA in Lipoderm showed markedly higher 
local tissue MPA levels and lower systemic MPA exposure as compared to values obtained 
after intravenous delivery of the same dose of drug (p < 0.05).
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Conclusion: We successfully developed for the first time, a topical formulation of MPA in 
Lipoderm with optimal in vitro/in vivo permeability characteristics and no undesirable local 
or systemic adverse effects in vivo. Our study provides key preliminary groundwork for 
translational efficacy studies of topical MPA in pre-clinical large animal VCA models and for 
effectiveness evaluation in patients receiving VCA.
Keywords: mycophenolic acid, topical, formulation, permeability, immunosuppression, VCA
INTRODUCTION
Over the past two decades, vascularized composite 
allotransplantation (VCA) has restored functional, psychosocial 
and quality of life outcomes in more than 250 patients suffering 
from devastating, unreconstructable extremity, craniofacial, 
genitourinary or other tissue defects. (1, 2)
The skin component of VCA (unlike in other solid organs), is 
touted to be the most immunogenic component and offers unique 
opportunities for graft monitoring (clinicopathologic correlation of 
rejection) and graft access for management (site-specific therapies). 
(3, 4) Conceivably, site-specific graft immunosuppression could 
reduce systemic exposure and global collateral or end-organ 
adverse effects of chronic systemic immunosuppression, which 
remains the “state of the art” in VCA. (5–8)
Currently, tacrolimus (TAC) (Protopic™ ointment 0.1%, 
0.03%, Astellas), and clobetasol (Temovate ® ointment, cream 
0.05%, GlaxoSmithKline), are FDA approved for topical use 
in certain dermatological conditions. (9–13) These topical 
immunosuppressive drugs have been used in VCA, off-label, to 
treat acute rejection pro re nata (PRN). (14) Despite their efficacy, 
these formulations are associated with undesirable local side effects. 
Topical TAC can cause local skin irritation and erythema associated 
with burning sensation, itching and pruritus. Importantly, the 
greasy formulation reduces medication adherence in patients (15–
17) Topical clobetasol is associated with skin thinning or atrophy 
due to the impairment of collagen synthesis. (18–20)
With the exception of tacrolimus or clobetasol, there are no 
commercially available topical formulations for other widely 
used systemic immunosuppressive drugs such as mycophenolic 
acid (MPA), sirolimus (rapamycin, RAPA), and everolimus. It is 
therefore imperative to investigate the feasibility of developing 
alternative topical immunosuppressive drug formulations with 
independent or synergistic efficacy and safety profiles. (21) 
Developing an optimal topical formulation of MPA addresses this 
timely clinical need in VCA.
MPA is the active form of mycophenolate mofetil (MMF), which 
is an immunosuppressive drug used in solid organ transplantation 
(SOT). Unlike calcineurin inhibitors like cyclosporine and 
tacrolimus, MMF is not associated with nephrotoxicity or 
hepatotoxicity. (22–26) Over the past two decades, MMF has 
been used in triple therapy regimens in combination with TAC 
and prednisone in SOT (27–29) or VCA. (30–32) It has also been 
used in dual therapy in combination with RAPA in VCA. (33, 34)
MPA is available commercially in an enteric-coated form as 
mycophenolate sodium (Myfortic ®, Novartis) or the ester prodrug 
MMF (CellCept®, Roche), (8, 9). In vivo, the prodrug MMF is 
converted by hydrolysis to MPA (10, 11). This conversion occurs 
in blood, liver, kidneys and to a small extent in skin (12). MPA is 
metabolized by glucuronyl transferase to form MPA glucuronide 
(MPAG), which is an inactive metabolite that is excreted in the 
urine and bile. (35) In addition to its immunosuppressive effects, 
MPA has antibacterial, antifungal, antiviral, and antitumor 
properties. (36–38) MPA exerts its effects on T and B cells by 
reversible inhibition of inosine monophosphate dehydrogenase 
(IMPDH), an enzyme essential in the de-novo-synthesis of 
guanosine nucleotides required for DNA and RNA synthesis. (39, 
40) Despite its therapeutic efficacy, systemic use of MPA/MMF 
has been associated with undesirable gastrointestinal (nausea, 
diarrhea, abdominal cramps, constipation, vomiting and anorexia) 
and genitourinary adverse effects (urgency, frequency, dysuria, 
hematuria and sterile pyuria). (41–43)
Topical drug administration of MPA in VCA could facilitate 
minimization of overall number of drugs, dosing, frequency 
and duration of systemic immunosuppression while improving 
its anti-rejection efficacy and effectiveness in graft survival. (3) 
Furthermore, such strategies could allow graft targeted delivery 
with predominantly localized action, reduced risk of systemic side 
effects, avoidance of first pass intestinal/liver metabolism, ability 
to administer multiple drugs in combination and potential for 
minimization of drug-drug interactions. (4–6, 21)
For efficacy, any transdermal drug formulation and delivery 
must first consider the challenging barrier of the stratum corneum 
in the skin. (44–47) Drugs with low molecular weight (≤500 g/
mole), and high lipid solubility offer superior skin penetration 
and are suitable candidates for topical administration. (48, 49) The 
goal of this study was to prepare a topical formulation of MPA with 
optimal in vitro/in vivo characteristics such as release, permeation, 
and tissue bioavailability for further safety, efficacy and feasibility 
evaluation in clinical VCA.
MATERIALS, ANIMALS, AND METHODS
Chemicals and Reagents
MPA powder was obtained from Sigma–Aldrich (St. Louis, MO, 
USA). Cremophor EL (polyethoxylated castor oil, Kolliphor 
EL®, BASF, Germany), and propylene glycol USP were obtained 
from Sigma–Aldrich (St. Louis, MO, USA). Lipoderm, Aladerm, 
Versabase and Emollient cream were manufactured by PCCA 
(Professional Compounding Centers of America). Semisolid 
formulations of MPA Aladerm, MPA Lipoderm, MPA mollient, 
and MPA VersaBase were compounded by Hieber’s pharmacy 
(Pittsburgh, PA, USA). Spectra/pro RC membrane discs, molecular 
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weight cut off (MWCO): 6–8000 Dalton, thickness 0.002 inches, 
diameter 33 mm, were purchased from spectrum chemicals ® 
(Rancho Dominguez, CA, USA). All the solvents were HPLC and 
MS grade and were obtained from Fisher Scientific (Pittsburgh, PA, 
USA). Sigmacote® siliconizing reagent for glass and other surfaces 
was obtained from Sigma–Aldrich (St. Louis, MO, USA).
Animals
All experiments were performed in accordance with a protocol 
independently reviewed and approved by the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC). 
Animals (inbred Male Lewis rats aged 8 to 10 weeks, weighing 
about 200 to 250 g, Charles River Laboratories, Horsham, PA), were 
housed in a specific pathogen-free barrier facility and maintained 
in accordance with IACUC guidelines. All procedures were in 
compliance with American Association for the Accreditation of 
Laboratory Animal Care (AALAC) recommendations and the 
principles set forth in the National Institute of Health Publication 
80–23, Guide for the Care and Use of Laboratory Animals and 
the Animal Welfare Act of 1966, as amended. Rats were housed 
individually and in plastic Elizabethan collars to prevent oral 
ingestion of the topical formulations, and to prevent access of 
animal to the application site.
Methods
Assessment of Partition Coefficient of MPA in Octanol/
Water
Partition coefficient of MPA was experimentally measured to 
evaluate partitioning ability of MPA. 0.5–1 mg of drug powder 
was put in 2 mL tubes and sealed. One ml of 1-octanol and 1 
mL of potassium phosphate buffer (pH = 7.4) was added to the 
drug powder. After vortexing for 5 min and ultra-sonication at 
25°C for 15 min, samples were centrifuged for 5 min at 13,400 
rpm to facilitate phase separation, and allowed to stand for 1 h. 
The octanol was separated from the aqueous phase. Samples were 
diluted with acetonitrile and analyzed by high-performance liquid 
chromatography. The partition coefficient (log Po/w) as a measure 
of lipophilicity was calculated as follows:  log Po/w = log
(
C0/Cw
)
 , 
C0 and Cw are the concentrations of MPA in the octanol and water 
phase, respectively as per standard methods.
Preparation and Characterization of 
Semisolid Formulations
Semisolid formulations for MPA were compounded at Hieber’s 
pharmacy (Pittsburgh, PA, USA) using the following ingredients: 
MPA (Active ingredient), Propylene Glycol USP (wetting/
solubilizing agent), and water, Isopropyl Myristate, Phospholipids, 
Cetearyl Alcohol Triticum Vulgare (Wheat) Germ Oil, Cetyl alcohol, 
Stearyl alcohol, Ceteareth-20, Caprylic/Capric, Triglycerides, 
Glycerin, Dimethicone C13–14 Isoparaffin, Laureth-7, Xanthan 
Gum, Magnesium Aluminum Silicate Polyacrylamide, Disodium 
EDTA, BHT, Phenoxyethanol, Methylchloroisothiazolinone, and 
Methylisothiazolinone (Base/excipients). The prepared formulation 
was grossly examined followed by light microscopy for appearance, 
color, and aggregates or lumps. Texture and consistency was 
optimized to eliminate grittiness. All formulations were stored 
at 4°C.
Determination of in Vitro Release and 
Permeation (Penetration and Diffusion) of 
MPA in Solution and Semisolid 
Formulation
Permeation (partitioning and diffusion) of MPA in solution and 
four different semisolid formulations was simulated ex vivo in a 
Franz Diffusion Cell System (FDCS) usinga biomimetic membrane 
similar to human skin. The donor compartment was separated 
from the recipient compartment by a pre-hydrated biomimetic 
Spectra/Por® RC Membrane (0.002 inches thickness, 33 mm 
diameter, 0.45 µm pore size, MWCO: 6–8,000). (50) The effective 
diffusion area was 1.77 cm2. MPA in solution was prepared in a 
combination of cremophor 15% (Kolliphor EL®, BASF, Germany), 
ethanol 10%, and deionized water and the donor compartment was 
loaded with 400 µl of MPA (10 mg/ml) solution. Similarly, each 
semisolid formulation with MPA (0.5 g) was applied in the donor 
compartment. The aqueous recipient medium was magnetically 
stirred and maintained at 32–0.1°C on a hot plate. Samples were 
collected from recipient compartment at 0, 1, 2, 4, 6 and 24 h 
and replaced with the same volume of fresh recipient solution. 
Samples were analyzed by a validated HPLC assay developed in 
our laboratory. (51) All experiments were performed in triplicates 
and cumulative drug diffusion was calculated over a period of 24 h.
In Vivo Evaluation of Topical MPA in Rats
Naïve Lewis rats received either a single topical dose of MPA 
in Lipoderm (1%, 16.6 mg/kg), [n = 6], or IV bolus dose (10 
mg/kg), [n = 8]. The topical formulation was applied on the 
right or left hind limb of the rat. Tail vein blood sampling was 
performed at 0.08, 0.16, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h. 
Blood samples were centrifuged at 2100 ± 100 rpm for 10 min, 
at room temperature and the plasma was separated and stored 
frozen at −80 C until analysis. Rats were euthanized after 24 h 
following MPA treatment and tissues [skin, muscle, and draining 
lymph nodes (DLN)] were collected from both the application 
limb and contralateral limb for drug level measurement. Biopsies 
from skin and muscle were collected at 2, 6, 12, 24 h post dose 
administration for measuring drug concentration. The skin site 
was wiped with 50% ethanol prior to tissue sampling for MPA. 
Plasma and tissue levels of MPA were analyzed by modification 
of a prior published HPLC-MS/MS methodology (51).
Pharmacokinetic Analysis
Pharmacokinetic parameters after topical/systemic 
administration of MPA were obtained using Graph pad prism 
6 and Winnonlin 6. Peak plasma level (Cmax), and trough plasma 
level (Ctrough) were observed values. The area under the plasma 
concentration vs. time curve (AUC0–α) for MPA was determined 
by the linear trapezoidal rule. Clearance (CL) was calculated 
as  
Dose
AUC0−α .
The absolute bioavailability of MPA after topical administration 
was obtained as:
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F =
(
AUC0−α topical
)
(Dosetopical)
× Dose i.v.AUC0−α i.v. 
 
Assay Protocols
Quantification of MPA in Diffusion Medium by High 
Pressure Liquid Chromatography (HPLC)
Five hundred microliters of methanol were added to 50 µl of 
sample solution (MPA in medium). Samples were centrifuged 
for 3 min at 13,000 rpm after vortexing for 2 min at 3,000 rpm. 
Supernatants (50 µl) were analyzed with an HPLC protocol 
developed and validated for determination of MPA in a medium 
made up from a mixture of cremophor 15%: ethanol 10%: water. 
Separation was performed by a reversed phase SYMMETRY 
C18 column (100 Å, 5 µm, 4.6 × 250 mm) using Water Alliance 
System 2,695–2,998 with UV detection at 254 nm. Isocratic 
elution was performed with a mobile phase consisting of 30% 
water, 70% methanol, 0.1% formic acid (pH = 3), flow rate of 
1 ml/min, injection volume 50 µl, column temperature 37°C. 
MPA had a retention time of 4.2 min. The method was selective 
and reproducible in the range of 0.25–15 µg/ml with r2 of .9996. 
The lower limit of quantification (LLQ) was 0.25 µg/ml. The 
intraday and interday CV% at 0.5, 5 and 10 µg/ml were less 
than 10% (n = 3).
Quantification of MPA in Plasma by HPLC-
Tandem Mass Spectrometry (HPLC-MS/
MS)
Acetonitrile (500 µl extracting solvent) containing MPA-D3 (internal 
standard, 250 ng/L) was added to 50 µl of sample solution (MPA 
in plasma), followed by 200 µl zinc sulfate (0.1M). Samples were 
centrifuged for 3 min at 13,000 rpm after vortexing for 2 min, and 
supernatants (20 µl) were tested using a simple and reproducible 
HPLC-MS/MS method developed and validated for determination 
of MPA in plasma. Separation was performed by reversed phase 
HPLC-MS/MS using a Waters Atlantis dC18 column (100 Å, 5 µm, 
2.1 × 20 mm). Gradient elution was performed with a mobile phase 
consisting of solvent A: 95% water, 5% methanol, 0.1% formic acid 
and 2 mM ammonium acetate, and solvent B: 100% methanol, 0.1% 
formic acid and 2 mM ammonium acetate with flow rate of 0.4 ml/
min, injection volume 20 µl, and column temperature 40°C. MPA 
was quantitated using internal standard MPA-D3 by a positive electro 
spray ionization mode using multiple reactions monitoring. MPA 
had a retention time of 7 min. The parent to product mass transitions 
(m/z) for MPA was 338.2→207.2, and MPA-D3 was 341.20→210.20. 
The method showed an acceptable linearity in the range of 0.3–25 
µg/ml with r2 of 0.9996. The lower limit of quantification (LLQ) was 
0.3 µg/ml. The intraday and interday CV% at 1, 5 and 10 µg/ml were 
less than 10% (n = 3). (51)
Quantification of MPA in Tissues by 
Homogenization and Drug Extraction
The skin sites for tissue sampling were first wiped down three 
times with ethanol-soaked gauze to remove residual topical 
formulation on the surface. Skin, muscle, and DLN samples were 
frozen with liquid nitrogen. A BioPulverizer (BioSpec Products, 
Inc.) was used to pulverize/fragment tissue samples into powder 
form, 0.1 g of which was homogenized with methanol using a 
Mini-BeadBeater-1 (Cole-Parmer North America). Homogenate 
was left over night in a sonicator to allow for complete extraction 
of the drug from tissues. centrifuged at. Supernatants were 
collected by centrifugation of extracted tissue homogenates 
(2,100 ± 100 rpm for 10 min) and evaporated in a sample 
concentrator. Drug residue was then reconstituted with plasma 
and tissue drug concentration was calculated as µg/g of tissue 
weight.
Statistical Analysis and Data Interpretation
Statistical analysis was performed using parametric tests as the 
data was compatible with normality assumptions (numerical, 
linear relationships, distributions had normal shape). Student 
t test was used for two groups and ANOVA was used when 
one independent variable with greater than two conditions 
or treatments and outcomes was evaluated and compared. All 
experimental results were expressed as the mean ± SD deviation 
(SD). A P value < 0.05 was considered statistically significant.
RESULTS
MPA Permeability and Drug 
Characteristics
The molecular weight of MPA is 320.34 g/mole. The partition 
coefficient (log P) for MPA was experimentally measured as 3.5 
± 0.1, while the predicted value was 3.8. The flux (Jss) value was 
3,842 ± 115 µg/cm2/h, while the permeability coefficient (Kp) 
was 9.8 × 10−8 cm/s.
Physical Characterization of Semisolid 
Formulation of MPA
The topical formulation demonstrated good homogeneity with 
absence of aggregates or clumping and excellent texture with no 
grittiness. The pH of the formulation was 5.4 ± 0.5 which is very 
comparable to the pH of native skin. (52)
In Vitro Permeation of MPA in Solution
The cumulative amount of drug permeated per unit area 1.77 cm2 
from the solution of MPA across membrane over 24 h is shown 
in Figure 1. MPA permeation across the barrier membrane in 
FDCS followed the Fick’s Law of passive diffusion, J = K.Cv/h, 
where J is flux, Cv is permeant concentration in vehicle, h is 
membrane thickness and K is the partition constant of the 
permeant between the membrane and vehicle.MPA in solution 
exhibited a steady state flux Jss (3.8 ± 0.1 µg/cm
2/h) with a 3% 
coefficient of variation (CV) of flux. Permeability Kp of MPA 
across the membrane was 1.1 × 10−7 ± 3.2 × 10−9 cm/s. A 
cumulative release amount of MPA in solution, plotted against 
the time, showed a linear profile with R2 of 0.969. Total amount 
of MPA permeated over 24 h was 163 ± 4.6 µg. 67.8% of the 
loaded MPA dose was released from the donor chamber over 
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24 h. 7% of the loaded MPA dose permeated over 24 h into the 
receptor chamber.
In Vitro Release Profile of MPA in 
Semisolid Formulation
The total amount of MPA permeated from four different 
formulations into the receptor chamber over 24 h from the plots 
is presented in Figure 2 and shown in Table 1. MPA in Aladerm 
exhibited a high initial release rate (2.5 × 10−05 ± 1.6 × 10−05 
cm/h) followed by MPA in Lipoderm (2.2 × 10−05 ± 4.7 × 10−06 
cm/h). MPA in emollient and MPA in VersaBase  exhibited a 
lower initial release rate (2.8 × 10−06 ± 1.5 × 10−06 cm/h).
MPA in Lipoderm exhibited steady state flux 
 (1.12 ± 0.24 µg/cm2/hr) and permeability (6.2 × 10−09 ± 1.3 × 
10−09 cm/s) across the biomimetic membrane in linear fashion. 
The cumulative release of MPA from Lipoderm, showed a linear 
single-phase profile (Gradual and sustained over prolonged 
period of time). (53) A high percentage of the loaded MPA dose 
was released, while only a small fraction of MPA permeated into 
the receptor chamber. Several models were tested with the data to 
select the model with the best fit for the total drug release kinetic 
profile. The Higuchi’s model was a good fit for our experimental 
data as it is one of the release kinetic models that describes the 
released amounts of compounds as a function of square root 
of time. The diffusion coefficient of MPA in the membrane was 
2.8 × 10−05.
In Vivo Profile of MPA After Topical 
Administration
The mean plasma concentration-time profile of MPA after single 
dose topical and/or IV administration is presented in Figure 3. 
Following IV bolus administration, the MPA concentrations 
were very high initially (71.8 ± 28 µg/ml), with concentrations 
declining quickly thereafter over time to reach low values (0.5 
± 0.7 µg/ml) at 24 h. Following topical administration, peak 
MPA concentrations (0.6 ± 0.3 µg/ml) were reached between 3 
and 4 h. Concentrations of MPA were very low, or undetectable 
(<0.3 µg/ml) at 24 h. The pharmacokinetic parameters of MPA 
such as systemic exposure (AUC 0–∞), maximum drug levels 
(C max), trough drug levels (C trough), and bioavailability after 
topical and/or IV dose in rats is shown in Table 2. The Cmax and 
AUC0–α values were much lower after topical administration as 
compared to systemic administration of MPA (****p < 0.0001). 
MPA concentrations in plasma and local tissues including skin, 
muscle, lymph nodes following a topical dose and/or IV dose 
in rats is presented in Figure  4 and shown in Table  3. MPA 
concentrations in limb tissues were much higher after topical 
administration as compared to IV administration (p < 0.05), 
which indicates the localization of drug delivery to the site of 
application. MPA concentrations in skin, muscle, and DLN 
after topical administration vs. IV administration (**p = 0.0123, 
***p = 0.0048, ***p = 0.0068). MPA concentrations in plasma 
and tissues collected from the application limb following a 
FIGURE 1  | Cumulative amount (Mean ± SD) of MPA permeated across a 
synthetic membrane from MPA solution vs. Time (n = 3). The cumulative 
release  amount of MPA in solution, plotted against the time, showed a linear 
profile with R2 of 0.969. Plateau state was not reached in 24 h. 
Highpercentage of MPA dose (67.8%) was released from the donor chamber 
over 24 h, and only small percentage (7%) permeated into the receptor 
chamber.
FIGURE 2 |  Cumulative amount (Mean ± SD) of MPA permeated per 
1.77 cm2 from semisolid formulations vs. Time (n = 3). Formulations tested 
include Aladerm, Lipoderm, VersaBase and emollient base. Of the four 
semisolid formulations tested, MPA in Aladerm exhibited a high initial release 
rate (2.5 × 10−05 ± 1.6 × 10−05 cm/h) followed by MPA in Lipoderm (2.2 × 
10−05 ± 4.7 × 10−06 cm/h). MPA in emollient and MPA in VersaBase exhibited 
lower initial release rates (8.1 × 10−06 ± 3.4 × 10−06 and 2.8 × 10−06 ± 1.5 × 
10−06 cm/h). The cumulative release of MPA from Lipoderm, showed a linear 
single-phase profile over time with R2. Most of MPA was retained in the 
membrane and only small amount of MPA slowly permeated into the receptor 
chamber (42 ± 5 µg).
TABLE 1 |  Mean total amount of MPA (Mean ± SD) permeated from four 
different formulations into the receptorchamber over 24 h (Mean ± SD, n = 3)
Formulations Total Permeated Amount over 24 h (µg) 
MPA in Aladerm 76.3 ± 31.5 
MPA in Lipoderm 42 ± 5 
MPA in Emollient 18.5 ± 7 
MPA in Versa Base 10 ± 3.3 
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topical dose in rats is much higher than MPA concentrations 
in the other contralateral limb tissues (p < 0.05) (Figure  5). 
MPA concentrations in skin, muscle, and DLN collected from 
application limbs vs. contralateral limbs (*p = 0.04, **p = 0.03, 
 p = 0.09). Time course of MPA concentrations in skin and muscle 
at 2, 6, 12, and 24 h following a topical dose (16.6 mg/kg) in rats 
is presented in Figure 6. Pharmacokinetic parameters of MPA in 
the skin and muscle following a topical dose (16.6 mg/kg) in rats 
(n = 3) is shown in Table 4. Peak plasma concentrations of MPA 
in skin and muscle were achieved 2 h after topical administration 
(20.4 ± 7 and 6.6 ± 1.6 µg/g respectively)/Thereafter, MPA 
concentrations declined over time to reach low values at 24 h 
post topical dose administration (3.2 ± 2.8 and 1.7 ± 1.5 µg/g 
respectively). Peak levels C max and total systemic drug exposure 
AUC0–α in the skin were higher than the values observed in the 
muscle (p = 0.01). MPA was cleared from the skin at a lower 
rate than from muscle (32 ± 1.2 vs. 68.6 ± 39.7 l/h). During the 
first 2 h, MPA concentration in the skin increased at a faster rate 
than in the muscle, with slope = 10.14 for skin and slope = 3.33 
in the muscle. After 2 h, the concentrations began to decrease 
in both tissues.
DISCUSSION
Upon topical application, MMF undergoes only limited or 
unpredictable metabolism to the active form, MPA in the skin. 
This is because, skin esterase levels are variable depending on 
the location of application. (54) Our study takes the logical 
approach to develop a topical formulation with MPA rather 
than MMF. Topical administration of MPA, the “active drug,” 
via the skin or mucosa in VCA circumvents the confounder 
of skin esterase activity  and  could improve effectiveness by 
predominantly concentrating drug levels in the graft, decreasing 
systemic exposure, and consequentially, off-target effects.
The use of topical MPA in VCA could also be synergistic with 
topical TAC or other agents. It could help minimize the need 
for systemic MMF, TAC or corticosteroids for the prevention/
treatment of allograft rejection, and augment anti-rejection 
efficacy and medication adherence in patients, while lowering 
risk of systemic adverse effects.
Topical delivery of MMF has been attempted in dermatology 
applications such as psoriasis, vitiligo, atopic dermatitis or allergic 
contact dermatitis with varying results. (55–58) Although MMF 
is relatively lipophilic, skin permeation may be challenged by 
the stratum corneum (SC) whichis a natural barrier that limits 
systemic drug absorption and exposure. A thickened SC is the 
FIGURE 3 | Plasma MPA concentrations (Mean +/- SD) following an IV bolus 
dose (10 mg/kg, n = 8) and/or topical dose (16.6 mg/kg, n = 6) in naïve Lewis 
rats. Following IV bolus administration, peak plasma concentration was 
reached at 0.08 h with 71.8 ± 28 µg/ml, and then concentrations quickly 
declined over time to reach low values (0.5 ± 0.7 µg/ml) at 24 h. Following 
topical administration, the peak MPA concentration was appeared between 3 
and 4 h with 0.6 ± 0.3 µg/ml, concentrations were very low, and undetectable 
(<0.3 µg/ml) at 24 h. Peak levels C max and total systemic drug exposure 
AUC0-α after topical administration was significantly lower than the values 
observed after IV bolus administration (****p < 0.0001).
TABLE 2 |  Plasma pharmacokinetic parameters of MPA (mean + SD) in rats after IV bolus (10 mg/kg, n = 8) or topicaldose (16.6 mg/kg, n = 6).
Route of administration Dose (mg/kg) AUC0–α (µg.h/ml) C max (µg/ml) C trough (µg/ml) CL/F (ml/h) Bioavailability (%) 
Intravenous 
administration 
10 34.4 ± 5.8 71.8 ± 28 0.5 ± 0.7 78.5 ± 16.8 100 
Topical administration 16.6 3.8 ± 1.1 0.6 ± 0.3 ND 1323 ± 355 6 
FIGURE 4 | MPA concentrations (Mean ± SD.) in plasma and local tissues 
(skin, muscle, DLNs) following a topical (16.6 mg/kg) or IV dose (10 mg/kg) in 
rats (n = 3). MPA concentrations in tissues were much higher after topical 
administration as compared to IV administration (p < 0.05), which indicates 
predominant localization of drug delivery at the site of application. MPA 
concentrations in skin, muscle, and DLNs after topical administration vs. IV 
administration (**p = 0.0123, ***p = 0.0048, ***p = 0.0068).
Feturi et al.
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cause of treatment failures in psoriasis with topical MMF (59) 
requiring the need for penetration enhancers such as eucalyptol 
(EUL) and N-methyl-2-pyrrolidone (NMP). (60) However, these 
enhancers inherently  cause skin irritation. (61)
To date, no study has compared the use of different formulation 
bases for topical delivery of MMF or MPA either in dermatology 
or VCA applications. Also, to our knowledge, a formal analysis 
of the pharmacokinetics and bioavailability of the active form of 
MPA, especially across the skin barrier has not been reported.
Ideally, topical delivery should be tested across a skin barrier. 
Excised human skin is considered the gold standard model for in 
vitro drug permeation and penetration assessment. (62) However, 
large variations are common across human skin explants due to 
differences in age, gender, race and anatomical donor site. (46) On 
the other hand, animal skins from pigs (porcine ear), guinea pigs, 
hairless mice or snakes (ecdysial skin) have been used as predictive 
model systems for in vivo human penetration/permeation 
oftopical agents. (63, 64) But, there is significant intra- and inter-
individual variation between animal and human skin, when skin 
characteristics, such as thickness of skin (especially SC), lipid 
content, density of hair follicles, and esterase enzyme activity 
in each model are compared. (65) Studies have shown that the 
skin of rodents, such as hairless rats and hairless mice, are more 
permeable than human skin using drugs/agents with different 
physicochemical properties. (66) Some of the critical parameters 
that cause such variability in permeation/penetration proﬁles in 
animal or human skin are effects of storage and freezing (use 
of cryopreserving agents such as 10% glycerol) that can cause 
alterations in skin hydration or electrical resistance. (66–68) This 
can alter permeability and the lag time of hydrophobic drugs 
such as MPA as tested in this study. Finally, there is no consensus 
on the use of an ideal cryoprotectant for skin preservation or 
the optimal storage time/conditionsfor frozen skin used for in 
vitro drug permeation/penetration studies.  (69)  To overcome 
these individual limitations with animal or human skin, and to 
optimize testing of the topical MPA delivery parameters, our 
study combined in vitro and in vivo evaluation of efficacy and 
safety of topical MPA for skin applications.
We first evaluated our formulations in vitro in a FDCS 
system across a regenerated cellulose dialysis membrane 
(SpectraPor® RC) that functions like a biomimetic skin barrier. 
Our choice of the FDCS system was based on its validated metrics 
(such as membrane parameters, cell dimensions, temperature, 
membrane treatment, stirring efficiency, sampling frequency).
MPA in solution exhibited a good steady state flux (CV 
3%) and permeability (Kp 1.1 × 10−7 ± 3.2 × 10−9 cm/s) across 
the biomimetic membranein a linear fashion (Fick’s law), and 
saturation or plateau state was not reached in 24 h. During 
the Franz cell run, the saturated state of MPA in solution 
was maintained  to keep the thermodynamic activity constant 
and sustain sink conditions via frequent sampling rates 
(every 15–30 min).
Careful correlation of characteristics such as permeability 
coefficient (P), diffusivity (D), and partition coefficient (K) for 
each of the four semisolid formulations tested were important 
considerations in our study. The highest initial release rate, mean 
steady state flux, permeability, and total permeation over 24 h 
were seen with MPA in Aladerm, followed by MPA in Lipoderm, 
MPA in emollient and MPA in VersaBase. MPA in Aladerm 
exhibited the highest diffusion and fast initial release (burst) 
and amount permeated to the receptor. This could indicate a 
propensity for rapid systemic absorption and high exposure 
with clinical use. Furthermore, Aladerm has a fluid texture 
that may lead to difficulty in application and maintaining the 
formulation on the skin for reliable absorption and efficacy. We 
thus excluded MPA in Aladerm from further testing. Similarly, 
we excluded MPA in emollient and VersaBase as choices for 
further development because of their thick and greasy nature, 
which challenges topical application (difficulty in washing, 
staining of clothes and reduced patient adherence). (70, 71)
Contrary to Aladerm, only a moderate amount of MPA 
permeated into the receptor chamber over 24 h with the Lipoderm 
formulation. The timeline and kinetics of drug diffusion and 
release were ideal with MPA in Lipoderm. This included gradual 
diffusion and sustained drug release which facilitates a prolonged 
local site-specific action of the drug. Also, the formulation 
was shelf stable (with no degradation or alterations in pH or 
composition) over 3 months of storage at 25°C. The pH of the 
formulation was close to natural skin pH (on average 4.7), (52) 
minimizing risk of irritation.
While a high percentage of MPA dose was released from MPA 
in solution, only small percentage permeated into the receptor 
chamber. However, in comparison to MPA in solution, we 
observed a lower total permeability of MPA from all semisolid 
formulations across the biomimetic membrane.Our in vitro 
data with both MPA in solution and semisolid formulation was 
robust and reproducible as our methodology and experimental 
conditions were kept constant throughout the FDCS runs.
Our in vivo results demonstrated that AUC0–∞, C max, and 
 C trough after topical delivery of MPA were markedly lower than the 
values obtained after systemic delivery of MPA. Low concentrations of 
MPAwere observed in skin and DLNs after 24 h with a single IV dose, 
indicating that multiple, high dose injections may be necessary to 
increase concentrations in these tissues. Conversely, the low systemic 
bioavailability of MPA as observed after topical administration was 
probably due to drug accumulation in the local tissues at the site of 
application. MPA concentrations in tissues (skin and muscle) collected 
from the application site after topical delivery were significantly higher 
than values observed after systemic administration.The SC barrier of 
the skin may also slow or limit the rate of systemic drug absorption 
and release into circulation. In fact, the skin component retained the 
TABLE 3 |  MPA concentrations (Mean + SD) inskin, muscle and draining lymph 
node (DLN) tissue and plasmafollowing IV bolus (10 mg/kg, n = 3) or topical dose 
(16.6 mg/kg, n = 3)
MPA Concentration IV Delivery Topical Delivery 
Skin 0.06 ± 0.05 4 ± 1.6 
Muscle 0.3 ± 0.2 1.85 ± 0.3 
DLNs 0.26 ± 0.2 1.2 ± 0.2 
Plasma 0.7 ± 0.1 0.2 ± 0.2 
Skin-Plasma ratio 0.085 20 
Muscle-Plasma ratio 0.4 3.2 
DLN-Plasma ratio 0.37 6 
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most drug with topical application of MPA in Lipoderm when levels 
across skin, muscle, DLNs and plasma were compared (Figures 4, 
5; Tables  3, 4). MPA concentrations in skin and muscle reached 
the highest values 2 h post-topical administration, which indicates 
relatively rapid uptake of the drug into the skin and muscle tissue. 
Drug levels gradually fell to reach low concentrations at 24 h post-
topical dose administration due to drug metabolism or clearance into 
the systemic circulation. Drug concentration in tissues (skin, muscle, 
and DLNs) collected from the application site was significantly higher 
than drug concentrations in tissues collected from the contralateral 
site (Figure 5). This confirms that MPA predominantly localizes to 
the site of topical application with limited dispersion to other sites 
remote from the zone of topical delivery.
The high drug levels in DLNs may relate to the hydrophobic/
lipophilic nature of MPA. It is known that lipophilic agents are 
preferentially taken up by the lymphatic system and the degree of 
uptake depends on factors such as particle size (size range 200–600 
nm), surface charge, molecular weight, and hydrophobicity. (72, 
73)  DLNs are the initial site of allorecognition, and thereby 
localization of higher concentrations of MPA in these 
tissues could curb innate or adaptive immune responses in 
VCA tissues.
Taken together, MPA in Lipoderm exhibited the optimal profile 
as the formulation of choice for topical use in clinical VCA. Future 
in vitro studies are being planned to evaluate the long-term stability 
of this formulation to determine the shelf life and optimal storage 
conditions consistent with clinical use.Studies are also underway in 
small and large animal VCA, to establish the effectiveness of MPA in 
Lipoderm (with or without low dose systemic immunosuppression) 
in preventing/reversing acute skin rejection or chronic vascular 
rejection, and sustaining allograft survival without systemic toxicity. 
In addition to its use as a single agent in topical therapy for VCA, 
MPA can be combined with topical TAC or RAPA for synergistic 
efficacy on T cell responses. (42) In fact, topical therapy combining 
MPA and RAPA provides complementary inhibition of Th2-related 
cytokines (IL-4) and Th1-related cytokines (IFN-γ) in atopic 
dermatitis.(57) Optimization of topical MPA formulations could thus 
lead to effective combination topical immunosuppression protocols 
(+RAPA ± TAC) for site-specific therapies (±low dose systemic 
immunosuppression) in VCA to prevent AR or chronic rejection. 
Potentially, targeting distinct mechanistic pathways and molecular 
targets in the skin immune system with a combination of topically 
effective, site-specific immunosuppression may facilitate a permissive, 
immunomodulatory milieu that enables prolonged graft survival in 
VCA with minimization of systemic immunosuppression and long-
term drug-related toxicity.
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FIGURE 5 | MPA concentrations (Mean ± SD) in plasma and tissues 
(application limb and contralateral limb) following a topical dose (16.6 mg/kg) 
in rats (n = 3). MPA concentrations in skin, muscle, draining lymph nodes 
(DLN) collected from the application limb following a topical dose in rats are 
much higher than MPA concentrations in the other contralateral tissues (p < 
0.05). MPA concentrations in skin, muscle, and DLN collected from 
application limbs vs. contralateral limbs (*p = 0.04, **p = 0.03, p = 0.09).
FIGURE 6 | Time course of MPA concentrations (Mean ± SD) in skin and 
muscle following a topical dose (16.6 mg/kg) in rats (n = 3). Peak plasma 
concentrations of MPA in skin and muscle were reached 2 h post-topical 
dose administration (20.4 ± 7 and 6.6 ± 1.6 µg/g), then concentrations 
gradually declined over time to reach low values at 24 h post topical dose 
administration (3.2 ± 2.8 and 1.7 ± 1.5 µg/g). Peak levels C max and total 
systemic drug exposure AUC0-α in the skin were higher than the values 
observed in the muscle (p < 0.01). MPA was cleared from the skin in a lower 
rate than the muscle (32 ± 1.2 vs. 68.6±39.7 l/h).
TABLE 4 |  Pharmacokineticparameters of MPA (Mean + SD) in the skin and 
muscle following atopical dose (16.6 mg/kg) in rats (n = 3)
Tissue Type AUC0–α (µg.h/ml) C max (µg/ml) C trough (µg/ml) 
Skin 168.5 ± 19 20 ± 7 3.2 ± 2.8 
Muscle 55 ± 9 6.6 ± 1.6 1.7 ± 1.5 
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